Pharmacosmos' revenue grows by USD 16m despite corona challenges

Investments in the US and China have affected Pharmacosmos' bottom line, but the company has increased its revenue and expects growth to continue in the new financial year.

Photo: Pharmacosmos / PR

In a previous accounting report, Pharmacosmos warned that it would probably end the year with a deficit on the bottom line, its first in 15 years -- and this prediction came true.

The company has ended its 2020/2021 financial year with a total deficit of USD 19.7m, a contrast to the USD 8m profit the company reported in its last accounting year.

Read the whole article

Get 14 days free access.
No credit card required.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Pfizer upgrades guidance for sales of covid-19 vaccine

The US pharmaceutical company Pfizer now predicts sales of its coronavirus vaccines will total USD 33.5bn this year. The previous estimate was UDS 26bn. Meanwhile, the company has revealed the guidance for its annual revenue.

Further reading

Related articles

Trial banner

Latest news

See all jobs